138 related articles for article (PubMed ID: 38430517)
1. Neural and metabolic dysregulation in PMM2-deficient human in vitro neural models.
Radenkovic S; Budhraja R; Klein-Gunnewiek T; King AT; Bhatia TN; Ligezka AN; Driesen K; Shah R; Ghesquière B; Pandey A; Kasri NN; Sloan SA; Morava E; Kozicz T
Cell Rep; 2024 Mar; 43(3):113883. PubMed ID: 38430517
[TBL] [Abstract][Full Text] [Related]
2. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
[TBL] [Abstract][Full Text] [Related]
3. Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG).
Thiesler CT; Cajic S; Hoffmann D; Thiel C; van Diepen L; Hennig R; Sgodda M; Weiβmann R; Reichl U; Steinemann D; Diekmann U; Huber NM; Oberbeck A; Cantz T; Kuss AW; Körner C; Schambach A; Rapp E; Buettner FF
Mol Cell Proteomics; 2016 Apr; 15(4):1435-52. PubMed ID: 26785728
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Cell Models to Study Monocyte Functions in PMM2 Congenital Disorders of Glycosylation.
de Haas P; de Jonge MI; Koenen HJPM; Joosten B; Janssen MCH; de Boer L; Hendriks WJAJ; Lefeber DJ; Cambi A
Front Immunol; 2022; 13():869031. PubMed ID: 35603178
[TBL] [Abstract][Full Text] [Related]
5. Primary ovarian insufficiency in a female with phosphomannomutase-2 gene (PMM2) mutations for congenital disorder of glycosylation.
Masunaga Y; Mochizuki M; Kadoya M; Wada Y; Okamoto N; Fukami M; Kato F; Saitsu H; Ogata T
Endocr J; 2021 May; 68(5):605-611. PubMed ID: 33583911
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the transcriptional program of phosphomannomutase 2-deficient cells: Lymphoblastoide B cell lines as a valuable model for congenital disorders of glycosylation studies.
Parrado A; Rubio G; Serrano M; De la Morena-Barrio ME; Ibáñez-Micó S; Ruiz-Lafuente N; Schwartz-Albiez R; Esteve-Solé A; Alsina L; Corral J; Hernández-Caselles T
Glycobiology; 2022 Mar; 32(2):84-100. PubMed ID: 34420056
[TBL] [Abstract][Full Text] [Related]
7. Liposome-encapsulated mannose-1-phosphate therapy improves global N-glycosylation in different congenital disorders of glycosylation.
Budhraja R; Radenkovic S; Jain A; Muffels IJJ; Ismaili MHA; Kozicz T; Pandey A; Morava E
Mol Genet Metab; 2024 Jun; 142(2):108487. PubMed ID: 38733638
[TBL] [Abstract][Full Text] [Related]
8. Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation.
Lao JP; DiPrimio N; Prangley M; Sam FS; Mast JD; Perlstein EO
G3 (Bethesda); 2019 Feb; 9(2):413-423. PubMed ID: 30530630
[TBL] [Abstract][Full Text] [Related]
9. Neurological manifestations in PMM2-congenital disorders of glycosylation (PMM2-CDG): Insights into clinico-radiological characteristics, recommendations for follow-up, and future directions.
Muthusamy K; Perez-Ortiz JM; Ligezka AN; Altassan R; Johnsen C; Schultz MJ; Patterson MC; Morava E
Genet Med; 2024 Feb; 26(2):101027. PubMed ID: 37955240
[TBL] [Abstract][Full Text] [Related]
10. International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up.
Altassan R; Péanne R; Jaeken J; Barone R; Bidet M; Borgel D; Brasil S; Cassiman D; Cechova A; Coman D; Corral J; Correia J; de la Morena-Barrio ME; de Lonlay P; Dos Reis V; Ferreira CR; Fiumara A; Francisco R; Freeze H; Funke S; Gardeitchik T; Gert M; Girad M; Giros M; Grünewald S; Hernández-Caselles T; Honzik T; Hutter M; Krasnewich D; Lam C; Lee J; Lefeber D; Marques-de-Silva D; Martinez AF; Moravej H; Õunap K; Pascoal C; Pascreau T; Patterson M; Quelhas D; Raymond K; Sarkhail P; Schiff M; Seroczyńska M; Serrano M; Seta N; Sykut-Cegielska J; Thiel C; Tort F; Vals MA; Videira P; Witters P; Zeevaert R; Morava E
J Inherit Metab Dis; 2019 Jan; 42(1):5-28. PubMed ID: 30740725
[TBL] [Abstract][Full Text] [Related]
11. Renal involvement in PMM2-CDG, a mini-review.
Altassan R; Witters P; Saifudeen Z; Quelhas D; Jaeken J; Levtchenko E; Cassiman D; Morava E
Mol Genet Metab; 2018 Mar; 123(3):292-296. PubMed ID: 29229467
[TBL] [Abstract][Full Text] [Related]
12. New and potential strategies for the treatment of PMM2-CDG.
Gámez A; Serrano M; Gallego D; Vilas A; Pérez B
Biochim Biophys Acta Gen Subj; 2020 Nov; 1864(11):129686. PubMed ID: 32712172
[TBL] [Abstract][Full Text] [Related]
13. A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2.
Chan B; Clasquin M; Smolen GA; Histen G; Powe J; Chen Y; Lin Z; Lu C; Liu Y; Cang Y; Yan Z; Xia Y; Thompson R; Singleton C; Dorsch M; Silverman L; Su SM; Freeze HH; Jin S
Hum Mol Genet; 2016 Jun; 25(11):2182-2193. PubMed ID: 27053713
[TBL] [Abstract][Full Text] [Related]
14. Hypolipidaemia among patients with PMM2-CDG is associated with low circulating PCSK9 levels: a case report followed by observational and experimental studies.
Chong M; Yoon G; Susan-Resiga D; Chamberland A; Cheillan D; Paré G; Seidah NG
J Med Genet; 2020 Jan; 57(1):11-17. PubMed ID: 31391289
[TBL] [Abstract][Full Text] [Related]
15. Initial diagnosis of the congenital disorder of glycosylation PMM2-CDG (CDG1a) in a 4-year-old girl after neurosurgical intervention for cerebral hemorrhage.
Stefanits H; Konstantopoulou V; Kuess M; Milenkovic I; Matula C
J Neurosurg Pediatr; 2014 Nov; 14(5):546-9. PubMed ID: 25192236
[TBL] [Abstract][Full Text] [Related]
16. Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications.
Ligezka AN; Radenkovic S; Saraswat M; Garapati K; Ranatunga W; Krzysciak W; Yanaihara H; Preston G; Brucker W; McGovern RM; Reid JM; Cassiman D; Muthusamy K; Johnsen C; Mercimek-Andrews S; Larson A; Lam C; Edmondson AC; Ghesquière B; Witters P; Raymond K; Oglesbee D; Pandey A; Perlstein EO; Kozicz T; Morava E
Ann Neurol; 2021 Dec; 90(6):887-900. PubMed ID: 34652821
[TBL] [Abstract][Full Text] [Related]
17. Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature.
Schiff M; Roda C; Monin ML; Arion A; Barth M; Bednarek N; Bidet M; Bloch C; Boddaert N; Borgel D; Brassier A; Brice A; Bruneel A; Buissonnière R; Chabrol B; Chevalier MC; Cormier-Daire V; De Barace C; De Maistre E; De Saint-Martin A; Dorison N; Drouin-Garraud V; Dupré T; Echenne B; Edery P; Feillet F; Fontan I; Francannet C; Labarthe F; Gitiaux C; Héron D; Hully M; Lamoureux S; Martin-Coignard D; Mignot C; Morin G; Pascreau T; Pincemaille O; Polak M; Roubertie A; Thauvin-Robinet C; Toutain A; Viot G; Vuillaumier-Barrot S; Seta N; De Lonlay P
J Med Genet; 2017 Dec; 54(12):843-851. PubMed ID: 28954837
[TBL] [Abstract][Full Text] [Related]
18. Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG).
Taday R; Grüneberg M; DuChesne I; Reunert J; Marquardt T
Orphanet J Rare Dis; 2020 Sep; 15(1):258. PubMed ID: 32962735
[TBL] [Abstract][Full Text] [Related]
19. Genotypes and estimated prevalence of phosphomannomutase 2 deficiency in Turkey differ significantly from those in Europe.
Yıldız Y; Arslan M; Çelik G; Kasapkara ÇS; Ceylaner S; Dursun A; Sivri HS; Coşkun T; Tokatlı A
Am J Med Genet A; 2020 Apr; 182(4):705-712. PubMed ID: 31981409
[TBL] [Abstract][Full Text] [Related]
20. A zebrafish model of PMM2-CDG reveals altered neurogenesis and a substrate-accumulation mechanism for N-linked glycosylation deficiency.
Cline A; Gao N; Flanagan-Steet H; Sharma V; Rosa S; Sonon R; Azadi P; Sadler KC; Freeze HH; Lehrman MA; Steet R
Mol Biol Cell; 2012 Nov; 23(21):4175-87. PubMed ID: 22956764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
